Celaid Therapeutics is a biotech company that develops cell therapies for blood cancer, intractable blood diseases, and genetic disorders.
Celaid Therapeutics has raised $3.6M in total funding. The most recent round was Series B. The last funding was announced in October 2025.
Celaid Therapeutics's investors include UTEC - The University of Tokyo Edge Capital Partners, Osaka University Venture Capital, SBI Group, Tsukuba Institute of Research, NEDO.
Celaid Therapeutics is headquartered in Hongo, Japan.
Celaid Therapeutics is a biotech company that develops cell therapies for blood cancer, intractable blood diseases, and genetic disorders.
Celaid Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Celaid Therapeutics — Funding & Investors." VCBacked, October 7, 2025, https://www.vcbacked.co/company/celaid-therapeutics. Accessed September 30, 2026.
VCBacked. (2025). Celaid Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/celaid-therapeutics
{{cite web |title=Celaid Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/celaid-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated